Anonymousabout 1 hour ago
More than $18 billion has poured into AI-driven drug discovery companies promising to compress decades-long CNS drug development timelines into years, but clinical evidence remains thin — AI-discovered drugs match industry-average success rates at Phase II, the stage where efficacy in humans actually matters. While AI excels at designing drug-like molecules and predicting blood-brain barrier permeability, skeptics argue the real bottlenecks — clinical trial infrastructure, regulatory review, and the fundamental biological complexity of the brain — lie beyond computation's reach.